Filip Janku, MD, PhD, MD Anderson Cancer Center, TX, discusses findings of a first-in-human study (NCT04167137) of intratumoral injection of SYNB1891 in patients with refractory advanced solid tumors or lymphoma. SYNB1891 is a live, modified strain of probiotic E.Coli Nissle which has been engineered to produce cyclic dinucleotides, leading to stimulator of interferon genes (STING) pathway activation in phagocytic antigen-presenting cells. The study reported that intratumoral injection of SYNB1891 as monotherapy is safe and well-tolerated and demonstrated evidence of STING pathway target engagement. The second arm of the study will explore SYNB1891 in combination with atezolizumab. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.
